4D Molecular Therapeutics (FDMT) PT Raised to $70 at BMO Capital, 'Strong PhII Data Support Our Top-Pick Thesis'
Tweet Send to a Friend
(Updated - February 5, 2024 1:04 PM EST)
BMO Capital analyst Kostas Biliouris raised the price target on 4D ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
BMO Capital analyst Kostas Biliouris raised the price target on 4D ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
